Novel anti-hypertensive mercaptoacylamino acid derivatives, their preparation and use.
17 claims: 10 independent, 7 dependent
- 1ΑΞΙΩΣΕΙΣ:I. “Ενας παρεμποδιστής ένζύμου μετατρέποντος τήν άγγειοτεν σίνην δ όποιος έχει τόν τύπον : R - Α - 3 - (0Η 2 )^ - CH - C - R ι 2 » /-4-καρβοξυλικόν ©1 είς τδν όποιον τό R εΐναι ύδρογόνον, φορμυλ, άκετύλ, προπανοϋλ, βουτανοϋλ φαινυλακετυλ, φαινυλοπροπανοϋλ, βενζοϋλ, κυκλοπεντυλσκαρβονυλ, τριτ-βουτυλοξυκαρβονυλ, κυκλοπεντυλοκαρβονυλ-Ε-λυσυλ,πυρο-Εγλουταμυλ-Ε-λυσυλ, Ε-άργινυλ, Ε-λυσυλ ή πυρο-Ιι-γλουταμυλ* τό Α είναι Ε-φαινυλαλανυλ, γλυκυλ, Ε-αλανυλ, Ε-τρυπτοφυλ, L-τυροζυλ, Ε-ισολευκυλ,Ε- λευκυλ, Ε-ίστιδυλ ή Ε-βαζυλ, ένω ή c-άμινοομάς αύτών εΐναι ένας δεσμός άμίδης μέ τό R* ύπό τόν cocv δτι τό φαινυλαλανυλ εΐναι ρακεμικόν δταν τό R είναι βενζοϋλ * τό Rj εΐναι ύδρογόνον μεθυλ’ τό R 2 εΐναι L-προλίνη, L-3,4-δευόροπρολίνη, Ε, Ε-3,4δεϋδροπρολίνη, E-3-υδροξυπρολίνη, E-4-υδροξυπρολίνη ή Ε-θειαζολι δ ίνηΓ έ νώ ή ίμινοομάς αύτών εΐναι ένας δεσμός ίμίόης μέ 0 τό γειτονικόν -5-* καί τό η εΐναι 0 ή I, ούτως ώστε δταν τό η - 0, Rj εΐναι μεθυλ.
- 2‘0 παρεμποδιστής τής άξιώσεως I είς τόν όποΓον τό R εΐναι βενζοϋλ Ρ. 1808 - 48
- 3’Ο παρεμποδιστής τής άξιώσεως I είς τόν όποΓον τό R εΐναι ύδρογόνον.
- 4‘θ παρεμποδιστής τής άξιώσεως I είς τόν όποιον τό R εΐναι φορμυλ, άκετυλ, προπανοϋλ, βουτανοϋλ, φαινυλακετυλ ή φαινυλοπροπανοϋλ.
- 5*0 παρεμποδιστής τής άξιώσεως I είς τόν όποΓον τό R εΐναι κυκλοπεντυ^οκαρβονυλ ή τριτ-ρουτυλοξυκαρβονυλ.
- 6‘0 παρεμποδιστής της άξιώσεως ϊ είς τύν όποΓον τό R εΐναι κυκλοπεντυλοκαρβονυλ-Σ-λυσυλ ή πυρο-Σ-γλουταμυλ—Σ-λυσυλ. 7ο *0 παρεμποδιχχής τής άξιώσεως I εις τόν όποΓον τό R εΐναι Σ-άργινυλ, L-λυσυλ ή πυρο-Σ-γλουταμυλ.
- 78. 'Ο παρεμποδιστής τής άξιώσεως I είς τόν όποιον τό R εΐναι βενζοϋλ, τό Α εΐναι φαινυλαλανυλ, τό Rj εΐναι μεθυλ, τό R£ εΐναι L-προλίνη καί τό η = Ι
- 89. Μία μέθοδος παρεμποδίσεως του ένζύμου μετατροπής άγγει τενοίνης έν ζωή (ΙΜ 7170) Η όποια περιλαμβάνει χορήγησιν μιας άποτελεσματικής ποσότητος μιας ένώσεως ή όποια έχει τόν τύπον ό όποιος περιεγράφη είς τήν άξίωσιν I.
- 910. Μία μέθοδος διά τήν έλάττωσιν τής πιέσεως τοΰ αίματος εν 5^5 (JR ϊίϊθ) θ όποία περιλαμβάνει χορήγησιν μιας άποτελεσματικής ποσότητος μιας ένώσεως ή όποία έχει τόν τύπον ό όποιος περιεγράφη εις τήν άξίωσιν I.
- 1011. Μία μέθοδος διά τήν παρασκευήν ένός παρεμποδιστού ένζύμου μετατροπής άγγειοτενσίνης δ-όποιος εΐναι χρήσιμος διά τήν άγωγήν τής ύπερτάσεως ό όποιος έχει τόν τύπον - 49 είς τό όποιον τό Ε είναι 'ψορμυλ, άκετυλ, προπανοϋ'λ, βουτα- /-4-καρβο-, ξυλικόν όξύ νοΰλ, φαινυλακετυλ, φαινυλοπροπανοϋλ, βενζοϋλ, κυκλοπεντηλοκαρβονυλ, τριτ-βουτυλοξυκαρβονυλ, κυκλοπεντυλοκαρβονυλ-Σ-λυσυλ ή πυρο-δ-γλουταμυλ* ϊό Α είναι L-φαινυλαλανυλ, γλυκυλ, L-αλανυλ, L-τουπτοφυλ, Ι-τυροζυλ, L-ισολευκυλ, L-λευκυλ, L-ιστιδυλ ή L-βαλυλ, ένω ή c-άμινοομάς αύτων είναι ένας δεσμός άμίδης μέ τό Ε, ύπό τόν όοον ότι τό φαινυλαλανυλ είναι ρακεμικόν, όταν τό R εΐναι δενζοϋλ* τό Rj είναι ύδρογόνον ή μεθυλ* τό R 2 είναι L-προλίνη, L-3,4-δεϋδροπρολίνη, D,L-5,4-0e06pc ποολίνη, L-3-υόροξυπρολίνη, L-4-υδροξυπρολίνη ή L-θειαζολιδίνή^ ενω ή ίυινοομάς αύτών είναι ένας δεσμός ίμίόης μέ τό γειτονιό II κόν - 0 - και τό η είναι 0 ή I, ούτως ώστε όταν τό η » 0, τό Ε- είναι .εθυλ, ή όποία περιλαμβάνει τάς ακολούθους βαθμίδαςϊ. υ |1 (1) άντίδρασιν E^-S-(CH 2 ) η-^Ε-C-OH μετά Ε^ ίνα λά τό E 3 -3-(GE 2 ) η-0Η-$-Ε2 όπου ’ Σ τόΕ^ είναι ακετυλ καί τά Rj, R^ καί η έχουν δρισ-άή ώς άνωτέρώ* (2) άποαάκρυνσιν τοΰ R, άπό τό προϊόν τής βαθμίδος (I) ίνα λάβωμεν τό HS-(GH 2 ) -GH-C-R 2 * 3ωπεν (3) άντίδοασιν τοΰ προϊόντος τής βαθμίδος (2) με R-Α ίνα ιι λάβωμεν το R-A-S-(CR 2 ^ - pH-C-R^ όπου ’ R T Ρ. I80S '/.Λ·' t- τά R, A, Rj, Rg καί η έχουν δρισθή ώς άνωτέρω. 12.. ‘Η μέθοδος τής άξιώσεως II είς τήν δποίαν ή άντίδρασις ή δποία περιεγράφη είς τήν βαθμίδα (I) διεξάγεται είτε παρουσία I, Ι-καρβονυλοδιϊμιδαζόλης είτε δικυκλοεξυλοκαρβοδιϊμίόης καί ή άντίδρασις ή δποία περιγράφεται είς τήν βαθμίδα (3) διεξάγεται παρουσία Ι,Ι'-καρβονυλοδιϊμιδαζόλης.
- 1113. ‘Η μέθοδος τής άξιώσεως 12 είς τήν δποίαν τό Rg είς τήν βαθμίδα (I) έχει έπίσης μία προστατευτικήν δμάδα διά τό καρβοξυλ τό δποΓον απομακρύνεται είς τήν βαθμίδα (2).
- 1214. *Κ μέθοδος τής άξιώσεως 12 είς τήν δποίαν τό 2 εΐναι βενζοϋλ. Ι5· ‘Η μέθοδος τής άξιώσεως 12 είς τήν δποίαν τό ?. εΐναι φορμυλ, άκετυλ, προπανοϋλ, βουτανοϋλ, φαινυλακετυλ καί φαινυλοποοπανοϋλ.
- 1316. *Η μέθοδος τής άξιώσεως 12 είς τήν δποίαν τό R είναι κνκλοπεντυλοκαρβονυλ ή τριτ-βουτυλοξυκαρβονυλ.
- 1417. ‘Η μέθοδος τής άξιώσεως 12 είς τήν δποίαν τό ?. είναι κικλοπεντυλο-καρβονυλο-Α-λυσυλ ή πυρο-Α-γλουταμυλ-Α-λυσυλ ·
- 1518. *Η μέθοδος τής άξιώσεως 12 είς τήν δποίαν τό Ξ. εΐναι Α-αργινυλ,Α-λυσυλ ή πυρο-Α-γλουταμυλ.
- 1619. ‘H μέθοδος τής άξιώσεως 16 είς τήν δποίαν τό A - S Ο , (SE 0 )_ - CH - δ - R 9 σχηματίζεται διά άποπροστασίας τοΰ τριτά. η t R-, βουτυλοξυκαρβονυλ-Α - S - (CHg)^ ~ R-T - R 9 είς τό ρ/_ι§08 -/.-=· 'ί’-./;'···'·.·, όποιον ? .! Τά A, Rj, R 2 καί η έχουν όρισθή ώς άνωτέρω.
- 1720. ‘Η μέθοδος τής άξιώσεως 12 είς τήν όποίαν τό R είναι
Independent claims17
524 paragraphs in 32 sections, as filed
ΒΑΣΙΣ_ΤΗΣ_ΕΦΕΥΡΕΣΕΩΣ<sup>7</sup> An enzyme that converts angiotensin (peptidyl dipeptide hydrolase, or ACS) plays a key role in the physiology of hypertension. The enzyme is capable of converting the angiotensin I decapeptide I, which in turn
AepArgV alTyrlloHi aProPheHi sLeu to an octapeptide, angiotensin II by removal of the carboxy terminus HISLEU. The symbols of different chemical modules are explained in the following Table:
<img file="GR73585B_D0001.tif" />
<img file="GR73585B_D0002.tif" />
χ ϊ »„ - ···. ./, »r '. · ··: -.
- /.<·
<td>Ala</td><td>s</td><td>L - olanine</td>
<td>Ar <</td><td>X</td><td>L - orginine</td>
<td>Asp</td><td>X</td><td>L - ospartic acid</td>
<td>Glu</td><td>X</td><td>pyro-L- glutamic acid</td>
<td>Gly</td><td>X</td><td>glycine</td>
<td>Hip</td><td>X</td><td>hippuric acid (benzoologic</td>
<td>His</td><td>X</td><td>L - histidine</td>
<td>II ·</td><td>X</td><td>L - isoleucine</td>
<td>Lea</td><td>X</td><td>L - leucine</td>
<td>Ph ·</td><td>X</td><td>1-phenylalanine</td>
<td>Pr ·</td><td></td><td>L - proline</td>
<td>Pr ·</td><td>X</td><td>L - 3,4 - dihydroproline</td>
<td>S »r</td><td>X</td><td>L - serine</td>
<td>Irp</td><td> -</td><td>L - tryptophan</td>
<td>Tyr</td><td>X</td><td>L - tyrosine</td>
<td>Val</td><td>X</td><td>L - valine</td>
<td>ACS</td><td>X</td><td>Anzymon which converts</td>
<td>Hepee</td><td></td><td>N-2-hydroxyethylpiperazino -</td>
. , τ - «· f it • ??
. * .. 'Λ ·.
*; · '* <; *' - * '? Α ·;
ethanesulfonic acid.
Ongiotensin I is formed under the influence of the enzyme renin, an endopeptidase present in the kidneys, other tissues and plasma, or acting on an α-2-globulin in the egg.
P. 1808
<img file="GR73585B_D0003.tif" />
- 3 'Blood pressure is affected by certain peptides which are found in the blood. One of them, angiotensin II, is a powerful antihypertensive agent. Another, or bradykinin, a nine-peptide in the ARGPROPROGLYPEESERPROPHZaRG series is a potent blood pressure lowering agent (blood pressure lowering agent). In addition to an immediate effect of increasing blood pressure, angiotensin II stimulates the release of aldosterone or which tends to increase the blood pressure it causes. retention of extracellular salts and fluids. * Angiotensin II is found in measurable amounts in the blood of normal people. However, it has been found in elevated concentrations in the blood of patients with renal hypertension.
<img file="GR73585B_D0004.tif" />
ACE activity is usually found in excess, in both normal and hypertensive individuals by the amount or dose required to maintain the observed angiotensin II levels. * However, a significant reduction in blood pressure has been found to be achieved in hypertensive patients treated with A3E inhibitors. [GAVRAS,!., Ei AL., HgW_ERGL._J, _MED ^ _29I, 817 (1974)}.
DETAILED DESCRIPTION OF
INVENTION The present invention relates to novel inhibitors thereof. AGE dpoii have tdn general type
R - A - 3 - (0H „) ^ - CH - C - R<sub>?</sub>
R;
ε'ις τδ δποίον
P. 1808
<img file="GR73585B_D0005.tif" />
Rs R is hydrogen, formyl, acetyl, propane; glutamyl.
A is L-phenylalanyl, glycyl, L-alanyl, L-tryptophyl, I-tyrosyl, L-isoleucyl, L-leukyl, L-istidyl or L-valyl, a compound or α-amino group thereof being an amide bond. with R, under which the phenylalanyl is racemic, when R is benzoCl.
/ -4-carboxylic acid
<img file="GR73585B_D0006.tif" />
Rj is hydrogen or methyl * R<sub>2</sub> is L-proline, I / -3,4-dehydroproline, D, L-3,4-dehydroproline, L-3-hydroxyproline, L-4-hydroxyproline or L-thiazolidine; μέ τό γειτονικόν - * καί τό <τ> εϊναι 0 ή I, ούτως ώστε δταν τδ η- 0, τό R- εϊναι υεθυλ.
All of the amino acids discussed herein are present in the L-stereotype unless otherwise noted. Phenylamine is racemic when R is benzoyl. These compounds inhibit ACE and are administered orally as effective anti-hypertensive agents.
Discovery of the inhibitory power of AC3 in the compounds of the present invention provides a methodical method for designing inhibitory compounds. * Although many other prior art inhibitors are derivatives of proline, or substitution of proline by other * amino acids has also been shown to be a potent inhibitor. Arginine, or phenylalanine and or alkanine are all effective counter-suppressants.
<img file="GR73585B_D0007.tif" />
<img file="GR73585B_D0008.tif" />
<img file="GR73585B_D0009.tif" />
of proline, so that it is not possible to determine a direction.
Substitution of P-3,4-oehydroproline with proline has been studied in several systems. Replacement of L5,4-APr at the 7-position of bradykinin gives a boadykinin derivative which is important. decreased physiological activity. * See FISHER, GH ΕΤ ΑΠ., ΑΗΟΗ. BIQSHEM. 5ΐ2ί5ί<sup>8</sup>Λ_2<sup>8</sup>2ι.<sup>82</sup> (1978). On the other hand, the replacement of L3,4-ΔΠ ahead of the 3,5 or 9 position of the 3PP inhibitor ^<sub>a</sub> of ACE enhances its inhibitory activity. However, today, it is not possible to proceed to a logical explanation of the difference between the observed results after a substitution of D for proline. Similarly, there is no clear picture of the effects of other producers of proline or similar substances which replace ACE inhibitors in various positions.
To date, the effect of the amino acid on the left side of sulfur in the above-mentioned formulas has not been determined. It has been thought that this amino acid acts as an additional recognition site for the enzyme. If this is true, it would be possible to expect that a compound with an amino acid there could be a better inhibitor. It was not known which amino acids would be effective in this position and if they were and which they could impregnate if they could inhibit the inhibitory activity of a given compound. Applicants found various amino acids. are also effective for hydroxyproline, and the derivatives of proline, L- and D, L- -, 3,4-dehydroproline and thiazolidine C
<img file="GR73585B_D0010.tif" />
- 6 are very effective antihypertensive agents and have great inhibitory effect on ACE.
The present invention will be further described by the following Examples. In these examples, thin layer chromatography (TLC) is performed using silica gel plates. The numerical systems of solvents for use in TLC methods are as follows.
(I) is methanol: chloroform, I: I (parts by volume). (2-) is benzene: Water: δξικόν δξύ, 9: 1 ^ 9 (parts per)<sub>Λ</sub>(3) εΐναι δξικόν δξύ: ΰδωρ: κ-βουτανόλη 26:24: 150 (μέρη κατ'ογκον). (4) is n-butanol: pyridine: dioxygen, 15: 10: 3: 12 (parts by volume) (5) is chloroform: methanol: ammonium hydroxide, 60: 45: 20 (parts by volume). pKR buffers for paper electrophoresis are: pH I.9-formic acid: acetic acid: Dop, 3i2:
2.5 (parts by volume) * ph 5.0-ethylene glycol: dicic acid: pyridine! Water, ISO: 6: 8.5: 885 (parts by volume). Tisbutyloxycarbonyl, benzoyl, acetyl, formyl, propanoyl, butanoyl, phenylacetyl and phenylpropane All amino acid derivatives are commercially available. 3EPHADEX G-IO, S-EPSADEX LE-20 and 33PHADEX G-25 are trademarks of PHA83 & ACIA, INC., UPPSALA, SWEDEN.
Example__Ι<sub>Λ</sub>
Quantitative π £> οσόιο ΐ σ_σ ^ 0 £ activities ΑΟΕ. For most of the experiments described herein the enzyme is quantified in 0.05 M HEPES buffer.
P. 1808 / / 1 / '- ->
<img file="GR73585B_D0011.tif" />
pH 8.0 which contains 0.1 M DTA01 and 0.75 M Na ^ XO ^. The substrate used was benzoyl-GlY — HISIiEU ips final concentration IXIO<sup>_2</sup>4 2 X 10 ”, together with about I3 O, OOOCH4 [JE} benzoyl & HUHSHEU (25 mg / mg).
The enzyme is diluted in the above buffer so that 40 microliters of enzyme containing the pH buffer solution is capable of hydrolyzing 13 of the substrate over an incubation time of 37 minutes at 0 ° C. To begin quantification, 40 microliters of enzyme and 10 microliters of water or inhibitor dissolved in water are pre-incubated for five minutes at 37 ° C. * Then, a 50 microliter substrate is added to initiate a reaction and the solution is incubated for 15 minutes at 37 ° C. To finish the reaction, add 1 ml. 0.1 M HCl and then add 1 ml. ethyl acetate. The mixture is stirred in a rotary mixer and centrifuged briefly to separate the phases.
An aliquot of 500 microliters of the ethyl acetate layer is transferred to a vial of oscillating liquid containing 10 ml. RIAFiUOR, trade name d ·. In determining the IgG values, the activity of the enzyme is compared in the presence of inhibited in a series of different concentrations to the absence of activity. παραμποδιστοΰ. An inhibitory concentration curve as a function of the percentage of inhibition gave the value
<img file="GR73585B_D0012.tif" />
- 8 Example 2.
Synthesis of o-acetylthiopropanul-P-propylene-tert-butyl ester
3-d-4-Tylthiopropanoic acid, 0.365 g;, is dissolved in 2 ml of redistilled tetrahydrofuran (THF) and cooled to 0 ° C. A cooled solution of cyclohexylcarbodiimone, I.2051 g is added. in 2 ml. Tei, and then a cooled solution of L-prolino-tert-butyl ester, 1 g, was added. The reaction mixture was stirred at 0 ° C for one hour and then overnight at 4 ° C. The reaction mixture was then filtered and the precipitate was washed with ethyl acetate. The filtrates of the filtrates are removed under reduced pressure in a rotary evaporator. The residue is dissolved inside. ethyl acetate which is then washed three times with cold IN citric acid, twice saturated twice with cold 1 NaH00<sub>7</sub> and three times with saturated HaCL. The solution is dried over anhydrous MGSO ^. The solvent is removed under reduced pressure in a rotary evaporator at> 0 ° C to give a clear, oily product in an efficiency of about 87 v / v. The product migrates as a single spot in thin layer chromatography within five solvent systems.
Example 3.
Synthesis of 5-mevacaptopropanoyl - I »- proline
The product from Example 2, 3-acetylthiosoptophanoylL-prolino-tert-butyl ester, 0.5 g. άναμιγνΰεται- ^ ± έ_ 4.5 Χ.έκ '
P. 1808
<img file="GR73585B_D0013.tif" />
5.3 Methanolic ammonia at room temperature under nitrogen for one hour before removing the acetyl molasses. The solvent is then removed at 25 ° C by rotary evaporator. After taking up the product in methanol and re-evaporating twice in a rotary evaporator, the clear oily residue is dissolved in ethyl ether, washed twice with 5% of potassium bicarbonate and dried once, saturated with M The solvent is removed in vacuo to give a clear oily product, which migrates as a spot in thin layer chromatography to three separate solvent systems. The tert-butyl protecting group is removed by reaction with trifluoroacetic acid in anisole.
Examples 4-6
<img file="GR73585B_D0014.tif" />
Substitution by 3-acetylthiopropanoic acid
2-acetylthiopropanoic acid, 5-acetylthio-2-B, 1-methylpropanoic acid in Example 2 and basically following the methods of Examples 2 and 3, the following compounds were obtained. By removing the tert-butyl protecting group with trifluoroacetic acid in anisole in the first step, the dicyclohexylamine salt may be formed to aid in the cleavage of the isomers. The acetyl protecting group can be removed in a second step using methanolic ammonia, as described in Example 3;
<img file="GR73585B_D0015.tif" />
2 ££ 2 ££ iI £ S
IO
Union
2- mercaptopropanoyl-L-proline
3-mercapto-2-D-methylpropanayl-I-proline
3-mercapto-2-I) -E-methylpropanoyl-E-proline
Example 7
Synthesis of 3-mercapto-2-methyl-propanoyl-E-3,4-dehydroproline.
L-3,4-dehydroproline (ZS ^ PRO), 1 mg, dissolve in DMP and the solution is cooled to 15 ° C. The solution is neutralized by the addition of I equivalent of N-ethylmorpholine. In a special reaction vessel at -IO ° C, an equivalent of 5-acetylthio-2-methyl-propanoic acid is mixed in equal volumes of DME after I.I. The first solution containing ZoO Ζ GEO is mixed with the second, which contains 3-acetylthio-2-methylpropanoate while maintaining the temperature at -IO ° C. The combined egg solutions are stirred for one hour at -IO ° C. The solution is then allowed to warm slowly to room temperature, the solvent is removed on a rotary evaporator under reduced pressure at 40 ° C.
Add ethyl acetate (25 / ml) and cool the solution to 0 ° C. Two ml are added. IN citric acid,<sup>: </sup>the two phases are mixed and then left to separate. The phases are separated by a separatory funnel and the organic phase is washed twice with two ml. IN citric acid '
P. 1808
<img file="GR73585B_D0016.tif" />
II -
<img file="GR73585B_D0017.tif" />
twice with saturated KaCL and finally dried over anhydrous MGSO ^. KGSO νεται is removed by filtration and the solvent is removed by rotary evaporation. The residue is dissolved and recrystallized from a non-polar solvent such as benzyl to give 3-acetylthio-2-B, 1-methylpropanoyl-I-3,4,-dehydroproline. When desired 2-D — methylisomer, remove the remaining acetonitrile (approximately; ml) and heat the solution to 40 ° C. Dicyclohexylamine equivalent is added and the solution is allowed to stand at room temperature overnight. The crystals are collected by filtration and washed three times with acetonitrile. When further purification is desired, it is possible to recrystallize the material from isopropanyl. * Acetylplate can be removed as in Example 3.
Examples of 8-II / -4-xapgoxylic acid
<img file="GR73585B_D0018.tif" />
"Substituting for L-1-3,4-deioroproline, L-3-hydroxypoline, L-4-hyroxyprolin or L-thiazolidine"; 7, we obtain the following compounds.
Example
Union
5-mercapto-2-Ώ-methylpropanoyl-E, L-3,4-δ eOdroproline
3-mercapto-2-I> -methylpropanul-II-3-hydroxnproline
P. I8C6
<img file="GR73585B_D0019.tif" />
3 * / ΰαράδειχ [ΐα_ 'Ενωσις
II
3-mercapto-2-I> -methylpropanoyl-i · -4-hydroxyprolin i
3-Mercapto-2-y-methylpropanoyl-P-thiazolidine / -4-carboxyxylicone
<img file="GR73585B_D0020.tif" />
-4-Mapgoy wood,<sup>7</sup> acid
Example 12.
Similarly, 3-acetylthio-2-methylpropanoic acid substitutes for 3-acetylthiopropanoic acid or 3-acetylthiopropanoic acid are substituted for the examples of 7-W. , L4-hydroxy-proline and L-thiazolidine ^ following basically the methods described.
sample__J3;
Composition of N.<sup>a</sup>- £ 3- (Ν<sup>a</sup>-acetyl-P-phenylalanylthio) -2-I> -methylpropanol} -P-pro. ίνης fiber.
In solution 41.5 mg N<sup>a</sup> -acetyl-P-phenylalanine in 0.5 ml. redistilled dimethylformamide (DME) is cooled in an ice-dry ice-acetone bath to -20 ° C. To this solution is added a cold solution of 35 mg of L, carbonyldiimidazole in 10 ml. DME '. The solution is stirred at -0 ° C for two hours and then added to a cold solution of 48 mg of 3-mercapto-2-B-methylpropanoyl-Eproline in 1 ml. DME which is neutralized by
- 13 i .'- ethylmorpholine. The reaction mixture was stirred at -IO ° C for an additional hour and then slowly warmed to room temperature. The solvent is removed under reduced pressure at 40 ° C and ethyl acetate is added to the residue. The mixture was cooled in an ice bath and washed with CLIN HCL and then washed three times with saturated NaCL solution. The organic solvent was removed by rotary evaporation after drying over anhydrous HGSO. The solvent was removed under reduced pressure to give 35.5 mg of said product, a product which was found to be homogeneous using TLC with solvent systems I, 2, and 5.
<img file="GR73585B_D0021.tif" />
Examples 14-21; Substitutes for N<sup>a</sup>-acetyl-glycine, H<sup>a</sup>-acetyl-alanine, N<sup>a</sup>-acetyl-tryptophan, N<sup>σ</sup>-acetyl-tyrosine, N<sup>a</sup>—Acetylisoleucine, N<sup>a</sup>-acetyl-leucine, N<sup>a</sup>-acetyl-histidine or N<sup>a</sup>acetyl-valine in N<sup>a</sup>-acetyl-phenyl-alanine In Example 13 and following essentially the method of Example 13, we obtained the following compounds.
Example * Ενωσΐ £ _
Ν<sup>a</sup>- £ 3- (Ν<sup>a</sup>-acetylglycylthio) -2-I) -methylpropanoyl} -II-proline
P.I808
<img file="GR73585B_D0022.tif" />
- 14 Παοάδειχιια
Μ<sup>a</sup>- ^ 3- (I ^ -acetyl-P-tr subtype) -2-L-methylpropanoyl) -L-proline.
Ν<sup>a</sup>- 0“(<sup>Ν</sup>“-Acetyl-1-tyrosylthio) —2-B-methylpropanul ^ -L-proline
Ν<sup>a</sup>- Γ 3- (Ν<sup>a</sup>-acetyl-P-isoleucylthio) -2-I) methylpropanoyl} -L-proline
Ν<sup>a</sup>- ζ / 3- (Ν<sup>a</sup>-acetyl-P-leucylthio) -2-I) -methylpropanoyl] -L-proline
ΪΓ<sup>a</sup> L 3- (Β<sup>a</sup>-acetyl-P-histidylthio) -2-C) -methylpropanoyl ^ -L-proline
H®- C 3- (Β<sup>σ</sup>-acetyl-P-valylthio) -2-I> -methylpropanoCol} -L-proline
Ν<sup>a</sup>- C 3- (Ν<sup>a</sup>-acetyl-P-alanylthio o) -2-3- methylapropanoyl] -L-proline
Example 22.
Similarly, derivatives of L-3,4-dehydroproline, DL-3,4-dehydroproline, L-3-hydroxyproline, L-4-hydroxy-proline and L-thiazalidzine are obtained by equipping the products of Examples 3-12. of 5-mercapto-2-I> -methylpropanoyl-I "-prolines in Examples 13-21 and substantially following the method of Example 13.
P. 1808
<img file="GR73585B_D0023.tif" />
- 15 Example 23.
* Substitutes by derivatives of N.<sup>a</sup>-formyl, N<sup>a</sup>-propanol, N<sup>a</sup>-βουτανοϋλ, Ν<sup>a</sup>-phenylacetyl or N<sup>a</sup>-phenylpropanol, LPh ·, Gly, L-Ala, L-Irp, L-Tyr, L-Ile, L-Leu, L-His<sup>KaC</sup>
L-Val the N<sup>a</sup>-acetyl derivatives of Examples 13-22 and following basically the method of Example 13, we obtain the formyl, propanoyl, butanul, phenylacetyl and phenyl tropane.
Example 24.
Composition of N.<sup>a</sup>- E3n £ Na-tert-butyloxycarbonyl-E-phenyl-alanyl othioethylpropane yl ^ -L-proline.
<img file="GR73585B_D0024.tif" />
In solution 133, mg N<sup>a</sup>tert-butyloxycarbonyl-E-phenylalanine (N<sup>a</sup>-BG0-L-PHE) in 0.5 ml. redistributed LM; Cool in an ice-dry ice-acetone bath to 20 ° C. To this solution was added a cold solution of 57 mg I, I'-carbonylimimidazole in 1.0 ml. DME. The solution is stirred at -IO ° C for two hours and then added to a cold solution of GF, 5 mg of 3-mercapto-2-E-methyltropanulL-propine in 1 ml. The reaction mixture was neutralized with Na ethylmorpholine. The reaction mixture was stirred at -0 ° C for an additional hour and then slowly warmed to room temperature. The solvent was removed under reduced pressure at 40 ° C and acetic acid was added to the residue.
• J!
<img file="GR73585B_D0025.tif" />
- The mixture is cooled in an ice bath and washed with G, 33i HCB and then three times with saturated NaOB solution. The solvent is removed by rotary evaporation after drying over anhydrous i'JGSO ^. The product is purified by liquid chromatography on oEPHAuEX G — BO to use
1.2 cm for 95 cm. column and eluted with THP: isopropanol, 3} 7 (parts by weight). The peak fractions were collected and the solvent was removed under reduced pressure to give 165 mm g. of the mentioned product. This product was found to be homogeneous using paper electrophoresis at pH 5.0 and using T1C with solvent systems 1,2 and 3.
Examples 25-32; Substitutes by N<sup>a</sup>-B00-glycine, N<sup>a</sup>-B00-alanine, N<sup>a</sup>-B00 tryptophan, iii<sup>a</sup>-B00-tyrosine s, ii<sup>a</sup>-B00-i sol efkine, N<sup>a</sup>BOC-leucine, N<sup>a</sup>-B00-histidine or N<sup>σ</sup>-B00-valine the P.<sup>a</sup>-30ORKE in Example 24 and following essentially the method of Example 24, the following compounds are obtained.
Example Union
N- ϋ3- (N<sup>a</sup>-trit-butyloxycarbonylglycylthio) -2-B-methylpropane] -B-proline
Ν<sup>a</sup>£ 3-tert-butyloxycarbonyl-B-tryptophylthio) -2-I) -methylpropanoylJ -B-proline.
N- E3- (N<sup><Σ</sup>-trit-butyloxycarbonyl-B-tyrosylthio) -2-B-methylpropanoyl3 -B-proline.
<img file="GR73585B_D0026.tif" />
<img file="GR73585B_D0027.tif" />
1ί «2άδει, χμα_
3C __Union
Ν<sup>a</sup>- ύ3- (Ν<sup>a</sup>-trit-butyloxycarbonyl-II-isoleucylthio) -2-E-methylpropanoyl3 -L-proline.
Ν<sup>a</sup>-C3- (H.<sup>a</sup>-trit-butyloxycarbonyl-L — leucylthio) -2-I) -methylpropanoyl7 -L-proline.
Ν<sup>a</sup>- ζ3- (Ν<sup>a</sup>-trit-butyloxycarbonyl-E — histidylthio o) -2-D-methylpropanol * λ'3-L-proline.
K<sup>a</sup>- [3- (Ν<sup>a</sup>-tri-butyloxycarbonyl-It-vanylthio) -2-B-methylpropanoyl) -E-proline.
Ν<sup>a</sup>- (3- (Ν<sup>a</sup>-trit-butyloxycarbonyl-x »-alanylthio) -2-Ώ-methylpropan0l} -L-proline.
Example 33 / -4- * no<sub>7</sub> , .xylic acid
<img file="GR73585B_D0028.tif" />
Similarly, the derivatives of E-3,4-dehydroproline, L, L-3,4-dehydroproline, L-3-hydroxyprolin, L-4-hydroxyprolin and Lithiazoline / are obtained by substitution for the products of Examples 3-12 of 3-mercap c-2-O-methylpropanoyl-Eproline in Examples 24-32 and if we have essentially followed the method of Example 24.
Example 34
Composition of H.<sup>a</sup>-cyclopentylcarbonyl-II-phenylanine.
A cold solution of 2.06 gr. dicyclohexylcarbodiimide in 10 ml. dichloromethane is added to a solution
<img file="GR73585B_D0029.tif" />
- 18 I.4114 gr. cyclopentanecarboxylic acid in 5 ml. dichloromethane at -5 ° C. Then I add 4.28 yp. The phenylalanine benzoyl ester toluenesulfonate in 10 ml of the solution is neutralized with 1.36 ml of 5-ethylmorpholine. The reaction mixture was stirred at 0 ° C for one hour and then at room temperature for three hours. Remove the bicyclohexylurea by filtration and 50 ml. δξικοΰ ethyl ester and are added to the filtrate. The organic phase is washed to neutral, dried over anhydrous MGSO δι and filtered, the solvent is removed by a rotary evaporator. The residue is crystallized from isopropanol and hexane to give 2.35 g of crystalline crystals having a melting point of 88-89 ° C. Elemental analysis of these crystals gives the following.
Calculated: C<sub>r</sub> 75.19 * Η<sub>=</sub> 7.17 * K = 3.9855
Found: C - 74.96 * E, -7.17 * K<sub>=</sub> 4.09 * The benzyl ester is removed by hydrogenolysis in 2 g. palladium on carbon 10 v / v in absolute alcohol. The catalyst is removed by filtration and the ethanol is removed by rotary evaporator. The residue is crystallized from ether and hexane to give 1.5 g of white crystals of the named product which has a melting point of I07-I08 C. C. Elemental analysis of these crystals gave the following.
Calculated: Cj 68.94 * H, 7; 33 * H, 5.36 Found: C, 68.90 * H, 7.32 * H, 5.34
P. 1808
- 19 The product was found to be capable of using paper electrification at pE 1.9 and pH 5.0 and using TLC with solvent systems, 1.2 and 3. What is the name?
product may be briefly referred to as N<sup>a</sup>-CpC — L-? HE.
Example 35
Composition of N.<sup>a</sup>^ - (^ ^ -cyclopentylcarbonyl-E-phenyl-alanyloth £ °) -1-L-proline.
In solution 52.5 mg. of the compound of Example 34 in 0.5 ml. IMF is cooled in an ice-dry bath. ice-acetone at -20 ° C. To this solution is added a cold solution of 34 mg. L * - carbonyldiimidazole in 1.0 ml. IMF, The solution is stirred at -IO ° C for two hours and then mixed with a cold 45.6 mg solution. 3-mercapto-2-E-methylpropanoCol-Lproline in I ml. ELISA which is neutralized by Ethylmorpholine. The reaction mixture was stirred at -IO ° C for an additional hour, and then slowly warmed to room temperature. The solvent is removed under reduced pressure at 4 ° C and concentrated ethyl ethers are added to the residue. The mixture was cooled and washed with CH 2 Cl 2 HCl and then shaken three times with saturated NaCl solution. The solvent is removed by a rotary evaporator after drying over anhydrous MGSO ^. The product is purified by oEPEADEX EH-20 στή '' column chromatography<sup>the</sup>use the 1.2 cm column. at 95 cm and eluted with isopropanol. The peak fractions are collected and the solvent is removed underneath
<img file="GR73585B_D0030.tif" />
reduced pressure to 60.5 mg of said product. This product has been found to be homogeneous using ILC in solvent systems I, 2, 3 and 5.
Examples 56-43 * Substitutes for the benzoyl ester toluene sulfonates of glycine, L-alanine, L-tryptophan, L-tyrosine, Lisoleucine, L-leucine, L-histidine or L-valine Example 1 and 34 Based on the methods of Examples 34 and 35, the following compounds are obtained.
5? £ ύόειγ [ΐα
Union
Ν<sup>a</sup>- (_ 3- (Κ<sup>a</sup>-cyclopentylcarbonylglycylthio; -2-L— methylpropanoyl ^ -L — proline.
Ν<sup>a</sup>- Ο- (Ν<sup>a</sup>-cyclopentylcarbonyl-T — tuptyl phylthio) -2-B-methylpropanoyl ^ -L-troline
L<sup>a</sup>- C 3- (1I<sup>a</sup>-cyclopentylcarbonyl -L— sulfate cheese) -2-3-methylpropanoyl3 -L-proline N<sup>a</sup>- Γ3- (Ν<sup>a</sup>-cyclopentylcarbonyl-S · - * soleukylthio ^ -2-I) -methylpropanul3 -L-troline B<sup>a</sup>- C 3- (Ν<sup>a</sup>-cyclopentylcarbonyl-S-leukylthio) -2-I> -methylpropamethyl3 -L-proin
Ν<sup>a</sup>- £ 3- (Ν<sup>a</sup>-cyclopentylcarbonyl-S-histidylthio) -2-I) -methylpropanoyl3 -L-proline.
K<sup>a</sup>- £ 3- (Κ<sup>a</sup>-cyclopentylcarbonyl — L-valylthio) -2-I) -methylpropanoyl ^ -L-propoline.
P.I308
<img file="GR73585B_D0031.tif" />
<img file="GR73585B_D0032.tif" />
- I
Example Union
Ν<sup>a</sup>- C3- (Ν<sup>σ</sup>-cyclopentylcarbonyl-P-alanylthio) -2-D-methylpropanoyl3, -L-proline.
Example 44
Similarly, the derivatives of P-3,4-dehydroproline, 1), 1 /, 4-dehydroproline, L-3-hydroxyprolin, L-4-hydroxyprolin and Lithiazoline are obtained by substituting the products of Examples 3-12 of 3. -mercapto-2-ΰ-methylpropanoyl L-proline in Examples 35-43 and if we follow basically the method of Example 35.
Example 45
Composition of N<sup>g</sup>- (3-L-9ainylanylanylthio-2-P-methylpr; panoyl) L-pol ivr, c_.
The product of Example 24 is deprotected by stirring a mixture of 30 mg of the product, 50 μl / L, anisole and 200 μl / anhydrous trifluoroacetic acid (TEA) at room temperature for one hour. The anisole is removed and the TEA is reduced under reduced pressure to 35 ° C and the residue is triturated with anhydrous ether. The white residue was purified by liquid column chromatography on 5EPm3) 3S G-10<sub>; </sub>use a 1.2 cm column. over 95 cm. and is eluted with acetic acid 5 v / o. The peak fractions are collected and lyophilized to give 17 · 5 mg of the named product.
<img file="GR73585B_D0033.tif" />
1808 This product was found to be homogeneous using paper electrophoresis at pH 1.9 and 5.0 and using TLC with solvent systems 4 and 5.
Examples 4th-53
Similarly, and following essentially the method of Example 45, the products from Examples 25-32 are demobilized and the following compounds are obtained.
example
4S
Union
Ν<sup>a</sup>- (3-glycylthio-2-I) -methylpropanol) -eprolin
Ν<sup>a</sup>- (3-Li-tryptophylthio-2-I) -methylpropanoCl) -II-proline ii<sup>a</sup>- (3-L'-tyrosylthio-2-D-methylpeopanoyl) L-proline
Ν<sup>a</sup>- (3-L-isoleucylthio-2-β-methyl opropanoyl-III-proline
Ν<sup>a</sup>(3-Li-leukylthio-2-B-methylpropanoyl) L-proline
Ν<sup>a</sup>- (3-I-histidylthio-2-I) -methylpopanoyl) L-proline
Ν<sup>a</sup>(3-II-valylthio-2-I) -methylpropanoyl) -Lproline
Ν<sup>a</sup>- (3-p-alanylthio-2-methylpropanol) -Hiproline
P.I808
<img file="GR73585B_D0034.tif" />
- 23 Example 54.
-4-£ οζυλικου
<img file="GR73585B_D0035.tif" />
<img file="GR73585B_D0036.tif" />
Similarly, the derivatives P-3,4-dehydroproline I), L-3,4-dehydroproline, L-3-hydroxyprolin, II-4-hyroxyproline and I-thiazolidine are obtained by deprotecting the compounds which are described in Example 33. '• is done if we follow basically the method of example 45.
Example 55.
Synthesis of cyclopentanecarboxylic acid by N-hydroxy-succinimide ester.
A cold solution II.4 g. dicyclohexylcarbodiimide in jDMF is added dropwise to a mixture of 5.71 g. cyclopentanecarboxylic acid and 5.76 g. H-hydroxysuccinide in DAD; at 0 ° C. The reaction mixture is stirred. 0<sup>c</sup>J for 30 minutes and continuously at 4 ° C overnight. The crystalline bicyclohexylurea was removed by filtration and the precipitate was washed with ethyl acetate. The solution is removed from the combined filtrates, removed under reduced pressure, and the residue is crystallized from benzene and hexane to give 5.77 g. white crystals having a melting point of 72.5 ° -73 ° C. The Infrared absorption spectrum in chloroform gave a typical H-hydroxyelectrimidoester spectrum. Elemental analysis of the crystals gave the following results.
Calculated: C, 56.86; H, 6.20 * N, 6.63 Found: C, 56.77 * H, 6.07 * N, 6.66.
P. 1808
<img file="GR73585B_D0037.tif" />
I
Example 56.
Composition of p<sup>K</sup>-cyclopentylcarbonyl-P<sup>£</sup>-trit-butyl-xycarbony. \ Echlysins.
In solution 1.2316 gr. Ν<sup>e</sup>-trit-butyloxycarbonyl-IL-lysine and 420 mg of NaHCO3 in 10 ml of water and 5 ml of THE are cooled in an ice bath under stirring. To this solution is added a cold solution of I.9 g. of the product of Example 55 in 10 ml. THE. Remove with a rotary evaporator at 35 ° C after the reaction mixture has been stirred overnight at room temperature. About 20 ml are added. of water in the reaction mixture and the pH is adjusted to 9 with solid HCl; The aqueous phase is extracted three times with ethyl acetate and the dogan chassis is discarded. The aqueous solution was cooled in an ice bath and then quenched to pH 2 with Hi HCL in the presence of ethyl acetate. The organic phase is washed twice with ice water and then with a solution of saturated PACI. The organic solution was dried over anhydrous L'GSO ^ and then filtered, the solvent was removed by a rotary evaporator and the residue was crystallized from ether and hexane to give I.35 g. white crystals which have a melting point. ΔΟ4.5 ° -ΙΟ5 · 5 ° Ο. Elemental analysis of the crystals gave the following.
Calculated: C, 59.63; H, 8.83; N, 8.18
Found: C, 59.74; H, 8.85; N, 8.24.
The product has been shown to be homogeneous using paper electrophoresis at pH 1.9 and pE 5.0 and using ILC of solvent systems 1.2. and 3;
P. 1808 & S
<img file="GR73585B_D0038.tif" />
Example 57.
Composition of N.<sup>a</sup>-cyclopentylcarbonyl-N<sup>e</sup>-trit-butyloxycarbonyl I-lysine-K-hydroxynilectrimidoester.
° In solution 1,027 g. of the product from Example 5 and 346 mg. E-hydroxysuccinimide in 10 k is desired at -5 ° C. To this solution was added with stirring a cold solution of 660 mg of dicyclohexylcarbodiimone of 5 ml. GEgCl ^. The reaction mixture was stirred at 0 ° C for 50 minutes and then at 4 ° C overnight. The crystalline cyclohexylurea was removed by filtration and washed with ethyl acetate. The combined filtrate was washed with 1 L / H 2 Cl 2, twice with water and finally with a saturated EaCL solution. * The organic phase is dried over anhydrous iI3SO ^, filtered and the solvent is removed by a peo-evaporator. The residue was crystallized from isopropanol to give 0.844 g. white crystals having a melting point of 140.5 ° C. Infrared absorption spectra in chloroform gave a typical spectrum of E-hydroxyelectrimido-spores. The chemical analysis of the crystals gave the following:
Calculated: C, 57.39; H, 7.57; N, 9.56 Found: C, 57.10; E, 7.57; N, 9.61.
Example 58.
Composition of H.<sup>a</sup>-cyclopentylscarbonyl-E<sup>e</sup>-trit-butyloxycarbonyl I-lysyl-E-phenylalanine,
P<sub>±</sub>_I808
<img file="GR73585B_D0039.tif" />
"In a solution of 220 mg, of the product from example 37 in 2 ml. dioxane is added dropwise to a mixture of 99.Z. χλστγρ. L-phenylalanine, and 51 mg. THE<sub>a</sub>HCl τός in a mixture of 2 ml. καίδατος και I κ.έκ. DMT. The reaction mixture was stirred at room temperature overnight and the dioxane was removed by rotary evaporation at 35 ° C; ethyl acetate (10 mL) was added to the reaction mixture, stirring, acidified to 0.1 ° C for 2 ° C. the aqueous solution is discarded. The organic phase was washed with ice water, a saturated HaCL solution, and dried over anhydrous iaG-SG ^, and the solvent was removed by rotary evaporation. The residual virus is crystallized from ether and petroleum ether (mp 30-60 ° C) to give 95 mg of a white solid which has a melting point of 90-92 ° C. The product has been shown to be homogeneous using paper electrophoresis at cH 1.9 and pE 5.0 and using TLC as systems I, 2, 5 and 4. Elemental analysis gave.
Calculated: C, 63.73 * N, 8.03 * N, 8.58
Found: 0, 63.40; H, 8.07; N, 8.34.
Example 59.
Composition of_N<sup>a</sup>- Γ3- (Ε<sup>a</sup>-cyclopentylcarbonyl-Ne-tert-butyloxycarbonyl-P-lysyl-E-phenyl alanylthio o) -2-3) -methylpopanol-L! proline.
In a solution of 73.5 mg of the product of Example 58 in 0.5 ml. redistilled DME is cooled inside
P._I80s
<img file="GR73585B_D0040.tif" />
<img file="GR73585B_D0041.tif" />
<img file="GR73585B_D0042.tif" />
ice-dry ice-acetone bath at -20 ° C. To this solution was added a cold solution of 26 mg I, L-carbonyldiimidazole in 1.0 ml. ΣώΕ. The virus solution is stirred at -ZO ° C for two hours and then mixed with a cold solution of 36 mg. 3-mercapto-2-D-methylpropanoyl-ii-proline, in I ml. PIF or dopia is neutralized by P-ethylmorpholine. The reaction mixture was stirred at -0 ° C for an additional hour and then slowly warmed to room temperature. The solvent is removed under reduced pressure at 40 ° C and acid ethyl ester is added to the residue. The mixture was cooled in an ice-water bath and washed with nitric acid and then three times with saturated NaCl solution. The solvent is removed by rotary evaporation after drying over MGSO. The product is purified by column chromatography on a 3CERAPECH LH-20 using a 1.2 cm column. for 95 cm. and eluted with TH »': isopropanol, 3: 7 (parts by volume). The peak fractions are collected and the solvent is removed under reduced pressure to give the named product which can be removed by abbreviation as K.<sup>a</sup>- 03- (Κ<sup>a</sup>-σ? σ-Η<sup>e</sup>-Bec-P-1Y3-P-PHE-thio) -2-Z> -methylpropane ^ -1-proline.
Example 60.
Composition of N<sup>g</sup>-t5- (n<sup>g</sup>—Cyclopentylcarbonyl-L · —lylyl-L — oenylalanylthio) -2-P-methylpropanoyl] -L-proline.
The Ne-BOC sample was removed from the lysine by stirring a mixture of 30 mg. of the product from example 59 to 50 liters of anisole and 200 liters of anhydrous__ i
<img file="GR73585B_D0043.tif" />
Refluxoacetic acid (TEA) at room temperature for one hour. The anisole and TEA are removed under reduced pressure at 35 ° C and the residue is triturated with anhydrous ether. The residue was purified by liquid chromatography on oEPHaDEX G-IO * using a 1.2 cm column. for 95 cm. and is eluted by 5 ο / ο δξικοΰ δξέος. The peak fractions are collected and lyophilized to give the named product which can be abbreviated to N<sup>a</sup>- (3- (N<sup>a</sup>--CPC-L — LYS-L-PKithio) -2-B-methylpropanoyl3 -L-proline.
Examples 6 ± -68
Substituting L-phenylalanine in glycine, L-alanine, E-tryptophan, L-tyrosine, L-isoleucine, L-leucine, L-histidine or L-valine in Example 58 and following the methods of the examples 58, 59 and 60, we obtain the following compounds.
__ 'Union
K<sup>a</sup>- C 3- (Ν<sup>a</sup>-cyclopentylcarbonyl-S-lysylglycylthio) -2-P-methylpropan0l3 -proline
ΙΔ<sup>a</sup>- [3- (Ν<sup>a</sup>-cyclopentylcarbonyl-1-lysyltryptophylthio) -2-E-methylpropane ϋ -L— proline
Ν<sup>a</sup>- (3- (Ν<sup>a</sup>-cyclopentylcarbonyl-E-lysyl-ethyrosylthio) -2-B-methylpropane; \ J -L-proline
P. 1805 l
<img file="GR73585B_D0044.tif" />
- 29 Example
6th
<img file="GR73585B_D0045.tif" />
Union.
Pi<sup>a</sup>- ζ3- (Ν<sup>σ</sup>'-cyclopentylcarbo nyl-P-lysyl-Lisoleucylthio) -2-I) -methylpropanoyl3<sup>_</sup>P-proline
Ιϊ<sup>σ</sup>'Γ3- (Ν'<sup>The:</sup>-cyclopentylcarbonyl-P-lys; yl-P-leucylthio) -2-P-methylpropanoyl] -L-proline
Ν<sup>a</sup>- [3- (Ν<sup>The:</sup>-cyclopentylcarbonyl-E-lyox, 'λ-Estidylthio) -2-B-methylpropanoyl} —L-proline
Ν<sup>a</sup>- (3- (Ν<sup>a</sup>-cyclopentylcarbonyl-E-lysyl-E-valylthio) -2-P-methylpropanoyl3 -L-pololine
Ν<sup>a</sup>- £ 3- (Ν<sup>a</sup>-cyclopentylcarbonyl-E-lysyl-I »alanylthio) -2-I) -methylpropanoyl ^ -E-proline / -4-xapgoy
<img file="GR73585B_D0046.tif" />
Example 69.
Similarly, the derivatives of L-3,4-dehydroproline, I, L-3,4-dehydroproline, L-3-hydroxyproline, L-4-hydroxyprolin and Lthiazoline / are obtained by substituting the products of Examples 3-12 of 3; -2-P-methylpropsnoyl-Eproline, Examples 59 and 61-68 and essentially if we follow the methods of Examples 59 and 50.
Example 70.
By substituting pyro-P-glutamic acid for cyclopentanecarboxylic acid in Example 55 and following essentially the methods of Examples 55-57,
- 1 ί
<img file="GR73585B_D0047.tif" />
P. 1808
- 30 λλάνομεν τόν Ν<sup>a</sup>-pyro-I-glutamyl-N<sup>e</sup>-trit-butyloxycarbonyl1-lysino-II-hydroxyelectrimidoester. By replacing this product for K.<sup>a</sup>-0P0-11<sup>e</sup>-300-1-DY3-11-hydroxy-succinimide ester in Example 58 and substantially following the methods of Examples 58-69, pyro-Glutamyl derivatives are obtained.
Example 71.
Preparation of pyro-P-glutamyl-P-phenylalaninebenzyl ester.
“In solution 0.52 gr. pyro-1-glutamic acid, 1.72 g. L-phenylalanine benzyl ester toluenesulfonic acid and 0.55 ml. N-ethylmorpholine in 5 ml. EME and 20 ml. dichloromethane is cooled in an ice bath under stirring. “In solution 0.826 gr. dicyclohexylcarbodiimide in 2 ml. dichloromethane is added to the above reaction mixture. The reaction virus is stirred in an ice-water bath for S hour and then at room temperature overnight.
The bicyclohexylurea is removed by filtration and the product is washed in ethyl acetate. Dissolves the combined filtrates are removed under reduced pressure under a rotary evaporator at 40 ° C. Add ethyl acetate (25 mL) to the residue and wash the organic solution to neutral. * The organic phase is dried over anhydrous MGSO ^, filtered and then the solvent is removed under a rotary evaporator. The material is crystallized from isopropanol and ether, didon I.OI g. white needles, m.p. The material was homogeneous in both the TL0 and electrophoresis systems. Elemental analysis gave:
<img file="GR73585B_D0048.tif" />
Calculated: C, 68.84; H, 6.05; H, 7.64
Found: C, 68.58; H, 6.05; N, 7.56.
Example 72.
Preparation of pyro-P-glutamyl-P-phenylalanine; 10 v / v (by weight) PJ_ on carbon in 0.15 ml. ice cream and 15 ml. ethanol at 20 PSI H<sub>2</sub> at room temperature overnight. The catalyst is removed by filtration. The dissolved solids are removed by rotary evaporator. The material is crystallized from isopropanol and benzene, "to give a total of 402 mg. crystals, m.p. I47-I49 ° C. The material was homogeneous by electrophoresis at pH 1.9 and pH 5.0 and by TLC in systems I, 2 and 3. Elemental analysis gave.
Calculated: G, 60.86 * H, 5.84 * E, 10.14
Found: C, 60.37; E, 5.85; H, 9.98.
Example 73;
Friday H.<sup>a</sup>- C3- (pyro-P-glutamyl-P-phenylal "nylthio) -2-RemethylpropanoylJ-P-proline.
“In solution 87 mg. I, I'-carbonyldiimidazole in 1.0 ml. Dffi? 139 mg of the product of Example 72 in 0.5 ml is added to a solution. DMF in - I5 ° C.
- The reaction mixture was stirred at -IO ° C for 1 hour, then a mixture of II.5.5 mg was added. 3-mercapto-2-I> methylpropanoyl-L-proline and 0.072 ml. N-ethylmorpholine in I ml. BME. The reaction mixture was stirred at -0 ° C for an additional 1 hour and then slowly warmed to room temperature. Remove under reduced pressure under a rotary evaporator to 40 ° C and then add 7 ml. δξικοϋ ethyl ester and 2 ml. I N citric acid. The organic phase is washed twice with N citric acid and twice with saturated NaCl. * The organic phase is dried over anhydrous MGSO ^ and then filtered, the solvent is removed using a rotary evaporator. Virus residue was purified by flash column chromatography on SEPHADEX G-25 (12 X 99 cm) with n-butanol: δxic acid = H2 O (4: 1: 5 by weight). The product was homogeneous according to TLC (systems I, 2 and 3) and electrophoresis pH 5.0.
Unbroken 74.
Substitutes for II<sup>a</sup>, Ν<sup>e</sup>-bis-tert-butyloxycarbonylL-lysine (hereinafter referred to as bis-BOC-L-LYS) or N<sup>a</sup>, Ν<sup>c</sup>, -triamadamyloxycarbonyl-B-arginine (or which is hereinafter referred to as tri-ABCO-III-arginine) is pyro-B-glutamic acid and essentially following the method of Example 71, the following three derivatives are synthesized: ALOC-I — AAA of L-PHE-benzene. Bis-BOC-LLYS is commercially available. The tri-ADOC-L-ARG-
<img file="GR73585B_D0049.tif" />
prepared in accordance with JAGER, G. A1TD GEIGER, R ,, QHEiil. BER._I03, 172.7 (1970).
Example 7th.
Substituents for the benzyl esters GLY, ALA, IRP, TYS KE, xEU, EIS or 7AL in the methods of parasamples 71 and 74, respectively, are pyro-P-glutamyl, bis-BOC-L-LYS and tri ARG derivatives. The former benzyl esters are commercially available. The benzyl ester groups are substantially removed as described in Example 72.
<img file="GR73585B_D0050.tif" />
Example 76.
The compounds resulting from Examples 72, 74 and 75 are reacted with any of the compounds resulting from the methods of Examples 3-12, if we follow essentially the methods of Examples 73, and give the opposite tracer-derivatives. L-IiYS and tri-Aoo-P-AKO. BisCl 3 and tri-ALOO protecting groups are removed by treatment with trifluoroacetic acid in anisole.
Following basically 71-76, they have examples 2-12. thioleesterone compounds any
R - A-S (0H<sub>2</sub>) ^ είς τό όποιον
Pl_I808 methods and procedure we take a family the general formula
CH
R,
<img file="GR73585B_D0051.tif" />
P is P-arginyl, P-lysy <or pyro-P-glutamyl *
<img file="GR73585B_D0052.tif" />
A is P-phenylalanyl, glycyl, L-alanyl, L-tryptosol, Lyrosyl, L-isoleukyl, L-leukyl, L-histodyl or L-valyl. wherein or α-amino is linked by anhydride to R; Rj is hydrogen or methyl; * 2 is L-proline, L-3,4-dehydroproline; -Hydroxyproline, L-4-hydroxyproline or L-thiazolidinedide wherein the iminoam is imidically attached to -5- * and it is C or I such that when / n = O, Lt Rj is methyl.
Example 77.
£ ύνθεσις_της N<sup>g</sup>—Ο- (Ν<sup>a</sup>-benzoyl-E-tryptophylthio) -2-E-methyl-<sup>! </sup>τ οοπαωοϋ ?! -ΰχπρ ολ ί νρς.
<sup>ν</sup>3rd solution 62 mg N<sup>a</sup>-benzul-I — tryptophan in O.p • ·. .from. Re-distilled imethylofoamamide (IMP) is cooled in an ice-dry ice-acetone bath to -20 ° C. To this solution is added: a cold solution of 35 kg<sup>f</sup>LP I, L'-carronylsedimidazole in 1.0 ml. IMF. The solution is stirred at -IO ° C for two hours and then added to a cold solution of 48 mg of 5-mercapto-2-B-methylpropanoyl-1-proline in 1 ml. DMF or supernatant is neutralized with X-ethylaorpholine. The reaction mixture was stirred at -IO<sup>c</sup>for an additional hour and then slowly warmed to room temperature, the solvent is removed under reduced pressure at 40 ° C and acid residue is added to the residue. ;
<img file="GR73585B_D0053.tif" />
I
- 55 ~
The crude mixture was cooled in an ice bath and washed with 0.1 L of HCl and then three times with saturated NaCl solution. The solvent was removed by rotary evaporation. after drying over anhydrous 1I6SO ^. The product was purified by liquid chromatography on CEPEAREX LH -20 using a 2 cm column. for 95 cm and eluted with isopropanol. The peak fractions are collected and the solvent is removed under reduced pressure to give 60.5 mg. of the product named as a foam material. This product was found to be homogeneous using TLC with solvent systems I, β, and 5.
Ί
<img file="GR73585B_D0054.tif" />
Examples 78-85.
^ ντικαθιστώντες διά Κ<sup>a</sup>-benzoyl-P-tyrosine, K.<sup>1</sup>—BenzoylL-histidine, II<sup>a</sup>- benzoylphenylalanyl, N<sup>a</sup>-benzoyl-glycine, iii<sup>a</sup>δ enzoyl-L — alanine, N<sup>a</sup>-8enzen-1-isoleucine, II<sup>a</sup>-benzoil-Leucine or N.<sup>a</sup>-benzene-P-valine the N<sup>a</sup>-benzoyl-P-tryptophan in Example 77 and substantially following the method "of Example 77, taking the following compounds:
—__ Ζ ιαραόειγμα.
Union
Ν<sup>a</sup>- £ 3- (Ν<sup>a</sup>-benzyl <-tyrosylthio) -2-D-methylpropanoyl] -P-proline
Ν<sup>a</sup>- £ 3- (Ν<sup>a</sup>-benzoyl-P-histyl diolithium) -2-D-methylpropan ϋ -L-proline.
Ν<sup>a</sup>- £ 5- (Ν<sup>a</sup>-benzoylphenylalanylthio) -2-Omethylpropanoyl ^ -L-proline
Ρχ_Ι808
<img file="GR73585B_D0055.tif" />
- 36 Example ': 85 ·' · «· ·. · <
'A
Ενωσΐ £ _
Ν<sup>a</sup>- (3- (Ν<sup>a</sup>-benzoyl-glycylthio) -2-B-methylpropanoyl-L-proline
K<sup>a</sup>- ^ 3- (Ν<sup>a</sup>-6enzoyl-α? <Anylthio) -2-methylpropanoyl} -L-proline
Ν<sup>a</sup>- ['3- (Ν<sup>a</sup>-benzoyl-P-isoleucylthio) -2-1-methylpropanoyl} -L-proline
K<sup>a</sup>- (? 3- (Κ<sup>a</sup>-benzoil-L-eukylthio) -2-i) -methylpropanoyl ^ -L-proline
Ν<sup>a</sup>- 3- (Κ<sup>a</sup>-benzoL-It> valylthio) -2-1-methylpropanoCl-L-proline.
Example 86.
/ -4-καρ £ ο-<sub>χ</sub>wooden ox
<img file="GR73585B_D0056.tif" />
<img file="GR73585B_D0057.tif" />
Similarly the derivatives of L-3,4-dehydroporoline, 8,1-3,4-hydropropoline, L-3-hydroxyprolin, -D-4-hydroxyprolin and 1-thiazolidine λαμβά are obtained by substitution for the products of Examples 3-12 of 3-part 2-I) -methylpropanoyl-proline in Examples 77-78 and if we follow essentially the methods of Example 77;<sup>a</sup>- £ 3- (Ν<sup>a</sup>-benzyl; phenylalanolthio) -2-I) -methylpropanoyl3-L-proline is described in the following two examples.
P. 1808
<img file="GR73585B_D0058.tif" />
<img file="GR73585B_D0059.tif" />
1,347 gr. benzoylphenylalanine and 0.576 g. N-hydroxysuccinimide Mix in a mixture of I.I. (by volume) THF and DI®. The mixture is incubated at 40 ° C overnight in the presence of 1.133 g. dicyclohexylcarbodiimide.
The reaction mixture is filtered off and the vector is removed under reduced pressure at 30 ° D. Remains a white residue which is recrystallized from THG - isopropyl alcohol. λην ΐνα δώση Ι.Ι94 γρ. (65.2 v / v) of a white solid, m.p. Ι56<sup>The</sup>0-I57 ° C. The infrared absorption spectrum in chloroform showed a 3440 cm band.<sup>-</sup>^, 1790 cm. ”^ And 1744 cm.
Example 88.
2. '2' ς Ν<sup>a</sup>- β - (Ν<sup>a</sup>-3-benzoylphenylalanylthio) -2-P — ethiopropanoyl -D-proline.
Reaction mixture containing 93.3 mg of 2D-methyl-3-mercaptopropanoyl-im-proline, 62 mg of L-hydroxybenzotriazine, all (HOBV), 165 mg of N-benzoyl-phenylacetate Example 87, is cooled in an ice bath to about 0 ° C, then 0.0544 ml are added. N-ethylmorpholine. The Reaction mixture is stirred in an ice bath, incubated for three hours at 4 ° C overnight and then at room temperature for twenty hours. The reaction is completed by the addition of 25 ml of N, N-dimethyl-1,4-propanediamine and stirred.
P. 1808
<img file="GR73585B_D0060.tif" />
i
<img file="GR73585B_D0061.tif" />
·.·.:
an additional two hours. Acetate acetate in the reaction mixture, which is then continuously washed by extraction with cold 0.1 K HCl, followed by two washes with water and three washes with saturated NaCl. The mixture was then dried over anhydrous KGSO δι and filtered, the solvent being removed under reduced pressure in a rotary evaporator to give a clear, oily product.
The product is purified by chromatography on LH -20 ***, 1.2. cm.9696. The column is eluted with THE and 2.5 ml fractions are collected. Fractions 30 and 31 were collected and given, after removal of the solvent under high vacuum, of II mg. product. Anhydrous ether is added and a white gum is obtained as material. The ether is decanted slowly and the white gum is dissolved as material in THF and transferred to a vial, dried under a stream of nitrogen and then further dried overnight. A foam of 82 mg is obtained as a product.
Fractions 25, 32 and 33 are chromatographed again under these conditions. Fractions 33 to 36 of the second chromatography are collected, treated as described and give an additional product of 51 mg. Overall yield was 71%.
An alternative method of preparing N<sup>a</sup>- ζ2-Ν<sup>a</sup>-benzoylphenyl ?. alanylthio) -propanoyl-L-3,4-dehydroproline and related derivatives is described in the following two examples,
Example 89.
Synthesis of 2-benzoylphenylalanyl thiopropionic acid.
?. 1308
<img file="GR73585B_D0062.tif" />
"In a solution of benzoylphenylalanine in 3 x ml. Dimethylformamide (DKF) was cooled to -2 ° C. Add a solution of I, I'-carbonyldiimidazole in 10 ml. re-distilled DME 'drip under violent agitation. The temperature should not be allowed to exceed -I4 ° C. The addition is followed, and the solution is stirred at -0 ° C for two hours. D, L-lactic acid in redistilled DMF or previously neutralized or redistilled H-ethyl_orpholine is then continuously stirred at -IO ° C for one hour. The virus solution is then slowly warmed to room temperature. Approximately one equal volume of diethyl ethyl ester is added. The mixture is then cooled and neutralized by concentrated ECL in saturated HaCL. The organic phase is then washed three times with supersaturated HaCL, i.e. five volumes of saturated HaCL diluted with one volume of Water. In some cases a three-layer E 'system is observed. In such cases, the middle layer is preserved through the lower aqueous phase. * The organic phase is dried over anhydrous MDF, filtered and placed in a rotary evaporator to remove the solvent. The or aqueous phase or the middle phase are quenched to 0 ° C with concentrated HCl to pE 2, and the ethyl acetate is extracted three times. The organic phase is washed with saturated iiaCL and dried over anhydrous magnesium sulfate, filtered and rotary evaporated. A clear oil is recovered.
P »1808
<img file="GR73585B_D0063.tif" />
- 40 Example 90.
Composition of E.<sup>a</sup>-ί2- (Ν<sup>a</sup>-benzoylphenylalanylthio-propanoyl1 -L ^ χ ^ χοευδοοποολ. ι νης_.
* B0C-L-3,4-cephoroproline (2S3 mg, C mg) is refluxed with 1 ml. anhydrous trifluoroacetic acid hxC I hour. Anhydrous is added. ethyl ester, 5 ml. The solvents are removed using a rotary evaporator at 30 ° C. The residue is washed three times with ether and then dried in a desiccator. vacuum over NaOH.
"In a solution of 353 mg (I mg) of the product from Example 39 in 5 ml. The redistilled PMP is cooled to -20 ° C in a dry ice-acetone bath. A solution of 171 mg (1.05 mg (1.05 mg) / ml of redistilled DMF is added dropwise to a solution of 1, 1 '' - carbonyldiimidazole, and the temperature of the reaction mixture is maintained at -C ° C to -5 ° C. The reaction is stirred for two hours. Add a cold solution of trifluoroacetate -3,4-dehydroproline in 2 ml. Didi 'i, neutralized by triethylin),
The reaction mixture is slowly warmed to room temperature. * The solvent is removed by rotary evaporation, using a vacuum at 35 ° C. The residue is dissolved in 10 ml. δξικοΰ ethyl ester and 2 ml. ΕΖ0. The mixture was quenched with N HCl to pX 2 at 0 ° C and mixed. * The organ phase is separated and stored. * The aqueous phase is extracted three more times for 5 ml. δξικοΰ αίθυλεστέρος.
The combined organic phase is washed twice with H 2 O, three times with saturated NaCl and then the activated carbon is decolorized.
<img file="GR73585B_D0064.tif" />
. I8CS
<img file="GR73585B_D0065.tif" />
<img file="GR73585B_D0066.tif" />
The organic phase is dried over anhydrous MGSO ται and then filtered. The filtrate was evaporated to dryness on a rotary evaporator to give an oily product, 366 mg. The product was purified by chromatography on SEPHADEX LE-2C (I2S98 cm), equilibrated and eluted with methanol. Fractions of 150 drops (2.9 ml) are collected. The desired compound is eluted in fractions 24-29. The solvents are removed by evaporation by rotation.
Additional purification is accomplished by a second step chromatography on SEPHADEX OH-2h. The second column is equilibrated and eluted with isopropanol, the peak fractions are collected and the solvent is removed by evaporation rotating. The product was about 95% pure and was separated by thin layer chromatography on a system of solvents (2) and (3).
ί.αράαειγμα 91.
<img file="GR73585B_D0067.tif" />
The inhibitory capacity of various of the above-synthesized compounds (IN VITRO (glass)) was measured in the quantification system described in Example I.
The enzyme preparation was purified from human urine as. described by AYAH, JW, ET Al., TISSUE FROM CELL IO 555 (1978). Table I shows the value for various compounds. The value is either the inhibitor concentration or the concentration required to cause 50% inhibition of the enzyme under a standard quantification system which contains substrates at substantially lower percentages of MS.
P.<sub>λ</sub>_Ι808
<img file="GR73585B_D0068.tif" />
<img file="GR73585B_D0069.tif" />
Π_ί_ν_α_ξ__I_.
“Union I
I
-i
<td>Example</td><td> 13</td><td> 2.6</td><td>X</td><td> 10<sup>-</sup>¾</td>
<td>Example</td><td> 24</td><td> 3.4</td><td>X</td><td> 10<sup>-</sup>¾</td>
<td>Example</td><td> 35</td><td> 7.5</td><td>X</td><td> 10<sup>-</sup>¾</td>
<td>Example</td><td> 45</td><td> 8.8</td><td>X</td><td> 10<sup>-</sup>¾</td>
<td></td><td></td><td> 2.5</td><td>X</td><td> 10<sup>-</sup>¾</td>
<td>Fish sample</td><td> 59</td><td></td><td></td><td></td>
<td>Example</td><td> 60</td><td> 1.5</td><td>X</td><td> 10<sup>-</sup>¾</td>
<td>Example</td><td> 77</td><td> 9.4</td><td>X</td><td> 10<sup>-</sup>¾</td>
<td>Example</td><td> 80</td><td> 2.5</td><td>X</td><td> 10<sup>-</sup>¾</td>
<td>Example</td><td> 81</td><td> 7.5</td><td>X</td><td> 10<sup>-</sup>¾</td>
<td>Example</td><td>90 (racemic)</td><td> 3</td><td>X</td><td> 10<sup>-</sup>¾</td>
Fish sample 92.
* Oral efficacy of various compounds.
Epianes (body weight 210-290) were fasted overnight and then anesthetized by intraperitoneal injection of pentobarbital, 50-60 mg / kg. A tracheotomy is performed and the animals are mechanically ventilated. "A catheter is inserted into the femoral vein for agiotensin injection and a second one. A catheter is inserted into a standard carotid artery to directly measure arterial blood pressure. Heparin is injected, 1000 units, through the femoral artery to prevent thrombosis. Blood pressure is measured by a pressure transducer connected to a polygraph.
P. 1808
<img file="GR73585B_D0070.tif" />
- 43 .-, .r · j
<img file="GR73585B_D0071.tif" />
The rats are injected with 160-400 ng / kg angiotensin I in 20 μl of 0.9 g of NaCl * or an amount of cast angiotensin I is sufficient to increase the mean blood pressure by 50 ° C. To restore the response to a certain strain of angiotensin I, the corresponding compound is administered at 5.5-23 mg / kg (drug dissolved in C.I.5 ml H 2 O plus 1C NaH gastric catheter. At regular intervals, the effects of 160-400 ng / kg angiotensin I on mean blood pressure were examined. The results are shown in Table 2. The dose of the individual compound is shown in parentheses behind the compound number. For example, 13 (I3; 6) means that Ip; 6 mg / kg of the compound from Example 13 are administered orally. The time, in minutes, after oral administration of the individual compound when tested, the effects of angiotensin I are shown in parentheses after reading on the control.
'' / '• / ή 2λ_Ι808 · - · Ί
<img file="GR73585B_D0072.tif" />
. '? . · .- 'X ο
CO Μ
H c .. 60 O CM c O
IfcFO M-j
Βθ O> <T
CJsO to ^ 4 CQ 'F
ί) 05 • to ® φ 'CPO ΟΟ. XX »w Φ
M Hl
Φ c Ρ «Η * 4
H η Φ Φ ± i P o CM -Η bO
Ό C o <o
1-4 U4 «ol A>
<td>u></td><td> 0</td>
<td>w-3</td><td> ►</td>
<td>U> P</td><td></td>
<td>o></td><td>c</td>
<td>V »H),</td><td></td>
<td>β 3.</td><td>C</td>
<td>a. ©</td><td>a</td>
<td>»-> a</td><td>The</td>
<td>O Q.</td><td> ►</td>
<td> - ·.©-</td><td> 6</td>
<td>»3 U</td><td></td>
<td>OX</td><td> 3</td>
<td>V * X u></td><td> 1</td>
<td>. · Ω<sup>:</sup> 3</td><td> 0</td>
<td>u> ω</td><td>l ·</td>
ω »e * c to υ> α * H> r> e
U »> o H '-» «* · © Hot r> OC *<sup>1 </sup>Ol JXUX «'
The XVK
XX Ό
Ο · ΟΌ H f * »V · * r> O -fa«
0 Ox fc -: l & H
Ο ΓΔ | σν cm
VO * f4 ·
CO ΓΉ to © co mo
oo oo ^ sr ^ srcovo ^ vor ^^ stvoo oooof * -r * rHsouo * Txn <o <CHuoo
<td>F—,</td><td>r— »</td><td> 1</td><td>F — l</td><td></td><td>r— »</td><td>rH</td><td>F— »</td><td> 1—. 1—»</td><td></td><td>r—></td><td>EARTH</td><td>cs</td><td>cs</td><td>m</td><td>Earth</td><td>O</td>
<td>m</td><td> ^4</td><td>r— «r4</td><td>CS</td><td>co</td><td>co σ \</td><td>in</td><td> ©</td><td>rs <r</td><td>CS</td><td>CS</td><td>CO</td><td> *4</td><td>in</td><td>CO</td><td>o</td><td>CO</td>
<td> 1</td><td> £</td><td>VO 1-4</td><td>cs</td><td>cs</td><td>co co</td><td> *4</td><td>vO</td><td>vo r *</td><td> 00</td><td>σν</td><td>f4</td><td>f4</td><td>r4</td><td>f-4</td><td>CS</td><td>cs</td>
<td></td><td></td><td>* —J · - ·</td><td></td><td> *—'</td><td></td><td></td><td> ·—'</td><td>k ~ _i WfZ</td><td>l__J</td><td></td><td></td><td></td><td>t — 1</td><td></td><td></td><td></td>
<td> ©</td><td>m</td><td>mm</td><td>cs</td><td> 00</td><td>f-4 CO</td><td>PH</td><td>Ph</td><td>U0 Earth</td><td>pH</td><td>r *</td><td>m</td><td>in</td><td>pH</td><td>fO</td><td>σ \</td><td> -4</td>
<td> ©</td><td>Ov</td><td>σν σν</td><td>OV</td><td>vo</td><td>vo m</td><td> %4</td><td><r</td><td>• 4 -ί</td><td> •4</td><td><r</td><td>m</td><td>m</td><td> *4</td><td>The</td><td>EARTH</td><td>P-</td>
<td>F — Ή</td><td>F— »1-F — t F—» F—- |</td><td><sub>r</sub>-<sub>9</sub></td><td> 00</td><td> 00</td><td>σν</td><td>m</td><td>m</td>
<td>CS</td><td>oo <rm oo oo</td><td> 00</td><td>r4</td><td>co</td><td>VO</td><td> 00</td><td> ©</td>
<td></td><td>• h cs co m vo</td><td> 00</td><td> »-4</td><td>F— <</td><td></td><td> »-4</td><td>cs</td>
<td></td><td> ·—»*—· . *—<sup>1</sup></td><td></td><td></td><td></td><td> •—<sup>1</sup></td><td></td><td></td>
<td>co</td><td>• -4 m vo \ o cs</td><td> ©</td><td>EARTH</td><td> ©</td><td>EARTH</td><td>Earth</td><td></td>
<td>ov</td><td>oo oo mmm</td><td>CO</td><td>co</td><td>vo</td><td>co</td><td>CO</td><td><r</td>
<td></td><td></td><td>r— »</td><td>r— »</td><td>rH</td><td>F—</td><td>F— »</td><td>F “</td><td></td><td>F- ^</td><td>F — Ί m</td><td>rH m</td><td>co</td><td>r ““% vO</td>
<td>sO</td><td>vO</td><td>CS</td><td>ST</td><td>m</td><td> 00</td><td>co</td><td>CO</td><td> 00</td><td> 00</td><td>oo</td><td> ©</td><td></td><td>cs</td>
<td> 1</td><td> +</td><td>f4</td><td>CS</td><td>co</td><td>O '</td><td>m</td><td>vO</td><td>pH</td><td> 00</td><td></td><td>cs</td><td>cs</td><td>cs</td>
<td> *—·</td><td>UJ</td><td></td><td></td><td> *—·</td><td>kJ</td><td> ·—·</td><td></td><td></td><td>uu</td><td>k ^></td><td> 1^»</td><td></td><td>k_</td>
<td>o</td><td>pH</td><td>PH</td><td>co</td><td>Earth</td><td>Earth</td><td>Earth</td><td> ©</td><td>pH</td><td>co</td><td>Earth</td><td>co</td><td>CO</td><td>co</td>
<td> ©</td><td>vO</td><td>m</td><td> *4-</td><td>co</td><td>F4</td><td>• H</td><td>CS</td><td>rH</td><td>f4</td><td>CS</td><td>co</td><td>co</td><td> *4·</td>
u> u>
-> 3, ϋ «ο -3 ©> o
M * - *
The
C - * h 9 Φ O 05 ex. oe ό o sz © sr:
o
Ph CS co © Γη cs © r * vo m O * 4 cs m co co cs <ro cs cs vO co. • -I co. i> * <.
**, · ',, Jk ·
-u, · »£
<td></td><td>Fn</td><td></td><td>F— »</td><td>F— »</td><td></td><td>Γ— “»</td><td>F— »</td><td>R 1— * F— »</td><td><sub>k</sub></td><td>sr</td><td>ri sr</td><td>F ^ * 4</td><td>vO</td><td> ^4 00</td><td>F-4 CO</td><td>vO</td><td>σν</td><td>R — T CS</td><td>vO</td><td>CS ©</td><td>F-4 f4</td>
<td>m</td><td>CO</td><td></td><td>F ^</td><td>AO</td><td>es</td><td> 00</td><td>o</td><td>vO © Ov</td><td>pH</td><td> ©</td><td> ^4</td><td>CS</td><td>CO</td><td>ST</td><td>pH</td><td> 00</td><td>σν</td><td>fH</td><td>CS</td><td><ro</td><td>σν</td>
<td>t</td><td> +</td><td>r **</td><td>CS</td><td>cs</td><td>co</td><td>co</td><td>m</td><td>m ρ * γη</td><td> 00</td><td> ^4</td><td></td><td>f-4</td><td> 1-4</td><td></td><td> »-4</td><td> ^4</td><td></td><td>CS</td><td>CS</td><td>cs cs</td><td>cs</td>
<td> *—«</td><td></td><td></td><td></td><td></td><td></td><td></td><td>U — 1</td><td>»- fc — 1 UJ</td><td> ·-—·</td><td> »“·</td><td> 4—.</td><td>k—></td><td> ·—*</td><td> *—·</td><td>k— »</td><td></td><td>fc— »</td><td><sup>l</sup>—·</td><td>u_</td><td>H— · - ·</td><td>k_.</td>
<td> ©</td><td>cs</td><td> *4“</td><td>cs</td><td> ©</td><td> ©</td><td> ©</td><td> 00</td><td>00 00 o</td><td>cs</td><td>CS</td><td> ©</td><td> ©</td><td>o</td><td>vO</td><td> 00</td><td>oo</td><td>oo</td><td> *4</td><td> •4</td><td>o ©</td><td> 4</td>
<td> ©</td><td>σν</td><td>vO</td><td>co</td><td>HT</td><td> *4</td><td>cs</td><td></td><td>cs</td><td> ^4</td><td> ^4</td><td>CS</td><td> *4</td><td> •4</td><td>CO</td><td> *4</td><td> -4</td><td>VO</td><td>vo</td><td>VO</td><td>OO 00</td><td> 00</td>
<td>r — ι</td><td>F — 1</td><td></td><td>F — 1</td><td>r—,</td><td>F — I</td><td></td><td>F — 1</td><td>r —- t</td><td>t</td><td></td><td>rt</td><td>ρ—,</td><td>γ— ^</td><td>p—,</td><td>o</td><td> ©</td><td>cs</td><td>cs</td>
<td>m</td><td>f4</td><td>r— ^</td><td>m</td><td> 00</td><td></td><td>in</td><td>σν</td><td>OA</td><td> *4</td><td>σν</td><td><r</td><td> ©</td><td> *4</td><td>aO</td><td>r4</td><td>cs</td><td>co</td><td> *4</td>
<td> 1</td><td>HH</td><td>m</td><td>f-4</td><td> ^4</td><td>CS</td><td>es</td><td>cs</td><td>CO</td><td><T</td><td> *4</td><td>m</td><td>AO</td><td>PH</td><td> 00</td><td> ^4</td><td>f4</td><td></td><td></td>
<td> ·—·</td><td></td><td></td><td> *—·</td><td>t—</td><td>u—.</td><td></td><td></td><td>V_l</td><td> ·—*</td><td> *—-»</td><td> *—·</td><td></td><td>UF</td><td></td><td> ·—·</td><td>I—.</td><td> *—·</td><td> ·—<sup>4</sup></td>
<td> ©</td><td>co</td><td>AO</td><td>vO</td><td>VO</td><td></td><td>F “4</td><td> *4</td><td> 00</td><td>vO</td><td>νθ</td><td>oc</td><td> 00</td><td> 00</td><td>f4</td><td></td><td>vo</td><td>AO</td><td>AO</td>
<td>o</td><td>m</td><td>aO</td><td>es</td><td>CS</td><td>CS</td><td>CS</td><td>CS</td><td> ^4</td><td>f4</td><td>f4</td><td>r4</td><td> ^4</td><td>f4</td><td>CS</td><td>CS</td><td>cs</td><td>cs</td><td>es</td>
<td>Fr »</td><td>1—4 F— »· ί—.</td><td>FH.</td><td>FH</td><td>F—. «4</td><td></td>
<td>m in</td><td>o in ^ 4 pH</td><td>mm</td><td></td><td>co ©</td><td></td>
<td>ί +</td><td>«-4 fM CO CO</td><td>* 4 m</td><td>co</td><td>o -</td><td></td>
<td> ·— <sup>k</sup>“-’</td><td>»- · v— · i—» -</td><td>k—</td><td> *—·</td><td>k — 4</td><td></td>
<td>© σν</td><td> -4 -4 *4 00</td><td> •4 -4</td><td>AO</td><td>AO 00</td><td></td>
<td>om , 4</td><td>* 4 «4 * 4 CO</td><td><r * 4</td><td>co</td><td>co co</td><td> .</td>
<td></td><td></td><td></td><td></td><td></td><td>r—</td>
<td>in \ o</td><td>© m in σν</td><td> 00 ©</td><td>pH</td><td>m * 4</td><td>CO</td>
<td> 1 +</td><td>«-4 -4 cm cs</td><td>co m</td><td>m</td><td>The EARTH</td><td>CO</td>
<td>UJ UJ</td><td> ·—' <</td><td>»- v— *</td><td>k — 1</td><td> ·—* ^-<sup>1</sup></td><td>UF</td>
<td>© P- *</td><td>Ov \ O 00 00</td><td>co co</td><td> ^4</td><td>• -4 \ O</td><td>\ O</td>
<td>© ΓΗ ^ 4</td><td>vO * 4 CO CO</td><td>co co</td><td>co</td><td>co cs</td><td>co</td>
<td> #—1</td><td>F — t</td><td>F-4</td><td></td><td>F— «</td><td>F—</td><td>r — 4</td><td>r — i</td><td>r—,</td><td>σν</td><td> *4</td><td> ©</td><td>PH</td><td>r4</td>
<td>m</td><td>CS</td><td>F-4 \ O</td><td>co</td><td>pH</td><td> 00 *4</td><td> ^4</td><td> «4</td><td>aO</td><td>o</td><td>CS</td><td> *4</td><td>in</td><td>PH</td>
<td>I</td><td>i</td><td>\ O ^ 4</td><td>cs</td><td>co</td><td>-4 Ό</td><td>P-</td><td> 00</td><td>σν</td><td>r-4</td><td></td><td>r — t</td><td> »-4</td><td> ,-4</td>
<td></td><td></td><td>U-. U_</td><td>k- ».</td><td> *—·</td><td>k_</td><td></td><td></td><td> ·—·</td><td> ·—»</td><td></td><td> •-·</td><td> *—·</td><td></td>
<td> ©</td><td> ^4</td><td>co σν</td><td>co</td><td>co</td><td>© AO</td><td>AO</td><td>PH</td><td>PH</td><td> ©</td><td> *4</td><td> ^4</td><td>CO</td><td>PH</td>
<td> ©</td><td>EARTH</td><td>AO * 4</td><td> 4</td><td> •4</td><td>* 4 CS</td><td>CS</td><td>co</td><td>CO</td><td><r</td><td>m</td><td>m</td><td>vO</td><td>Earth</td>
<td>m</td><td>CO</td><td> ^4</td><td>CS</td><td>σν</td><td> «4</td><td>r4</td>
<td> |</td><td> +</td><td> ^4</td><td>cs</td><td>cs</td><td>CO</td><td>m</td>
<td></td><td> ‘—<sup>1</sup></td><td></td><td></td><td> *—-</td><td> *—·</td><td></td>
<td> ©</td><td> ©</td><td>CO</td><td>pH</td><td> «4</td><td>cs</td><td>σν</td>
<td> ©</td><td>o</td><td> •4</td><td>cs</td><td>CS</td><td>cs</td><td>fH</td>
<td>m</td><td>co</td><td>«—Ι CO</td><td> ©</td><td>CO</td><td>fH</td><td> •4</td><td>cs</td><td>co</td><td> 00</td><td>PH</td><td> ©</td>
<td>I</td><td> +</td><td>Ph »-4</td><td></td><td>cs</td><td>CO</td><td>CO</td><td><r</td><td></td><td>m</td><td>V ©</td><td> 00</td>
<td></td><td> *“»</td><td>M k— »</td><td>H-4</td><td>«—J</td><td> ·—*</td><td> ·—‘</td><td></td><td> *—·</td><td></td><td></td><td> *—»</td>
<td> ©</td><td> ©</td><td>© CO</td><td> «4</td><td> ©</td><td>CO</td><td> ©</td><td> ©</td><td>vO</td><td>V ©</td><td> ©</td><td> ©</td>
<td> ©</td><td> •4</td><td>-4 CS</td><td>CS</td><td>cs</td><td>F · 4</td><td>cs</td><td>es</td><td>rt</td><td>rd</td><td>CS</td><td>cs</td>
<img file="GR73585B_D0073.tif" />
CS CS CO U “V h22L
4·:
TOT ·?
·.·'?', <sup>1</sup> •> 'fa'
A '- <*.? - 44. If J
<img file="GR73585B_D0074.tif" />
Example S3.
<img file="GR73585B_D0075.tif" />
Intravenous Efficacy of Various Compounds Anesthetized rats are prepared as described in Example 92. I 0.01 N sodium bicarbonate through the femoral artery. The effects of angiotensin I, 400 ng / kg on mean blood pressure, are examined at intervals. The results are shown in Table 3; * 0 Table 3 has the same shape as d Table 2.
ΙΪ ί ν α ξ ___ 3.
Blood pressure response to 400 ng / kg angiotensin I as a percentage of the fight £ minute after intravenous administration}.
Compound (dose.)
<td> 24</td><td> 60</td><td></td><td></td><td> 77</td><td></td>
<td> (2)</td><td> (2)</td><td></td><td></td><td> (2)</td><td></td>
<td>ΙΟΟ ο / ο 051</td><td>ΙΟΟ ο / ο</td><td>C-51</td><td>ΙΟΟ</td><td>ο / ο</td><td> 05}</td>
<td> 0 00.5]</td><td> 8</td><td></td><td> 8</td><td></td><td> 0+0.51</td>
<td>19 ΟΟ</td><td> 15</td><td>ΟΟ</td><td> 18</td><td></td><td>C50</td>
<td> 19 <3></td><td> 23</td><td> 040</td><td> 21</td><td></td><td>συ</td>
<img file="GR73585B_D0076.tif" />
- 46 24 6C '77 (2) (2) (2)
<td> 22</td><td><J3}</td><td> 23</td><td> 093</td><td> 24</td><td> 043</td>
<td> 31</td><td>CI80</td><td> 33</td><td>C240</td><td> 29</td><td>CE73</td>
<td> 31</td><td>C22)</td><td> 41</td><td> 073</td><td> 34</td><td>C2Q3</td>
<td> 50</td><td>C343</td><td> 46</td><td>C453</td><td> 42</td><td>C243</td>
<td> 63</td><td>C473</td><td> 46</td><td> 043</td><td> 47</td><td> 0£)</td>
<td> 78</td><td>C653</td><td> 46</td><td>C773</td><td> 53</td><td>C453</td>
<td> 75.</td><td>CtO33</td><td> 51</td><td> 073</td><td> 58</td><td>C4S3</td>
<td> 94</td><td>& Ι3)</td><td></td><td></td><td> 61</td><td>C563</td>
7i ΟΌ
7B & 6J
C8SJ
093
0253 While the invention is described in connection with a specific embodiment thereof, it is understood that it is capable of undergoing further modifications and that this application is intended to cover any variation, use, or adaptation thereof. in accordance with the general principles of the invention and comprising such escapes from the present description as presented in the ordinary practice of the technique to which the invention belongs and which may be applied in accordance with framework of the appended claims.
<img file="GR73585B_D0077.tif" />
- 47 CLAIMS:
Contents32
92 sheets
Sheet 1 Sheet 2 Sheet 3 Sheet 4 Sheet 5 Sheet 6 Sheet 7 Sheet 8 Sheet 9 Sheet 10 Sheet 11 Sheet 12 Sheet 13 Sheet 14 Sheet 15 Sheet 16 Sheet 17 Sheet 18 Sheet 19 Sheet 20 Sheet 21 Sheet 22 Sheet 23 Sheet 24 Sheet 25 Sheet 26 Sheet 27 Sheet 28 Sheet 29 Sheet 30 Sheet 31 Sheet 32 Sheet 33 Sheet 34 Sheet 35 Sheet 36 Sheet 37 Sheet 38 Sheet 39 Sheet 40 Sheet 41 Sheet 42 Sheet 43 Sheet 44 Sheet 45 Sheet 46 Sheet 47 Sheet 48 Sheet 49 Sheet 50 Sheet 51 Sheet 52 Sheet 53 Sheet 54 Sheet 55 Sheet 56 Sheet 57 Sheet 58 Sheet 59 Sheet 60 Sheet 61 Sheet 62 Sheet 63 Sheet 64 Sheet 65 Sheet 66 Sheet 67 Sheet 68 Sheet 69 Sheet 70 Sheet 71 Sheet 72 Sheet 73 Sheet 74 Sheet 75 Sheet 76 Sheet 77 Sheet 78 Sheet 79 Sheet 80 Sheet 81 Sheet 82 Sheet 83 Sheet 84 Sheet 85 Sheet 86 Sheet 87 Sheet 88 Sheet 89 Sheet 90 Sheet 91 Sheet 92
114 members in 25 offices
Priority claims36
| Document | Office | Kind | Date |
|---|---|---|---|
| 94128978 | United States of America | A | |
| 94128978 | United States of America | A | |
| 95818078 | United States of America | A | |
| 95818078 | United States of America | A | |
| 6489779 | United States of America | A | |
| 6489779 | United States of America | A | |
| 6489879 | United States of America | A | |
| 6489879 | United States of America | A | |
| 6489979 | United States of America | A | |
| 6489979 | United States of America | A | |
| 6490079 | United States of America | A | |
| 6490079 | United States of America | A | |
| 6490179 | United States of America | A | |
| 6490179 | United States of America | A | |
| 6490279 | United States of America | A | |
| 6490279 | United States of America | A | |
| 6490379 | United States of America | A | |
| 6490379 | United States of America | A | |
| 064897 | – | – | – |
| 064898 | – | – | – |
| 064899 | – | – | – |
| 064900 | – | – | – |
| 064901 | – | – | – |
| 064902 | – | – | – |
| 064903 | – | – | – |
| 941289 | – | – | – |
| 958180 | – | – | – |
| US19780941289 | – | – | – |
| US19780958180 | – | – | – |
| US19790064897 | – | – | – |
| US19790064898 | – | – | – |
| US19790064899 | – | – | – |
| US19790064900 | – | – | – |
| US19790064901 | – | – | – |
| US19790064902 | – | – | – |
| US19790064903 | – | – | – |
Members114
| Document | Office | Kind | |
|---|---|---|---|
| PT70158A | Portugal | A | |
| DK376179A | Denmark | A | |
| FI792806A | Finland | A | |
| AU5070579A | Australia | A | |
| EP0009898A1 | European Patent Office (EPO) | A1 | |
| PL218240A1 | Poland | A1 | |
| JPS5589230A | Japan | A | |
| ZA794723B | South Africa | B | |
| ES8100658A1 | Spain | A1 | |
| NO800675L | Norway | L | |
| NO855136L | Norway | L | |
| PT72635A | Portugal | A | |
| ZA803486B | South Africa | B | |
| IE810460L | Ireland | L | |
| DK93081A | Denmark | A | |
| FI810663L | Finland | L | |
| EP0035383A1 | European Patent Office (EPO) | A1 | |
| AU5922780A | Australia | A | |
| DK105981A | Denmark | A | |
| FI810725L | Finland | L | |
| NO810795L | Norway | L | |
| NO831111L | Norway | L | |
| NO831112L | Norway | L | |
| NO831113L | Norway | L | |
| NO831114L | Norway | L | |
| EP0038117A1 | European Patent Office (EPO) | A1 | |
| IE810967L | Ireland | L | |
| JPS56164115A | Japan | A | |
| JPS56164154A | Japan | A | |
| PL229971A1 | Poland | A1 | |
| PL231471A3 | Poland | A3 | |
| PT70158A1 | Portugal | A1 | |
| PT72635B | Portugal | B | |
| ES8203332A2 | Spain | A2 | |
| PL230076A1 | Poland | A1 | |
| DD156805A5 | German Democratic Republic (until 1990) | A5 | |
| NZ191524A | New Zealand | A | |
| NZ194002A | New Zealand | A | |
| DD158238A5 | German Democratic Republic (until 1990) | A5 | |
| AU7363181A | Australia | A | |
| PL124828B1 | Poland | B1 | |
| DD159426A5 | German Democratic Republic (until 1990) | A5 | |
| ES8305698A1 | Spain | A1 | |
| KR830000908A | Republic of Korea | A | |
| EP0009898B1 | European Patent Office (EPO) | B1 | |
| DE2965443D1 | Germany | D1 | |
| KR830005115A | Republic of Korea | A | |
| KR830005133A | Republic of Korea | A | |
| BG34463A3 | Bulgaria | A3 | |
| AU532424B2 | Australia | B2 | |
| IL58223A | Israel | A | |
| AU534945B2 | Australia | B2 | |
| ES8403104A1 | Spain | A1 | |
| ES8403448A1 | Spain | A1 | |
| ES8403449A1 | Spain | A1 | |
| ES8403450A1 | Spain | A1 | |
| GR73585BThis record | Greece | B | |
| EP0035383B1 | European Patent Office (EPO) | B1 | |
| DE3163812D1 | Germany | D1 | |
| GR74795B | Greece | B | |
| IL62203A | Israel | A | |
| KR840002357B1 | Republic of Korea | B1 | |
| IL62265A | Israel | A | |
| HUT35246A | Hungary | A | |
| CS615079A2 | Czechoslovakia (until 1993) | A2 | |
| KR850001629B1 | Republic of Korea | B1 | |
| HU187258B | Hungary | B | |
| PH19104A | Philippines | A | |
| CS242857B2 | Czechoslovakia (until 1993) | B2 | |
| NO154836B | Norway | B | |
| FI71749B | Finland | B | |
| IE51259B1 | Ireland | B1 | |
| NO154836C | Norway | C | |
| FI71749C | Finland | C | |
| IE51739B1 | Ireland | B1 | |
| ATA97081A | Austria | A | |
| NO156695B | Norway | B | |
| US4690937A | United States of America | A | |
| US4690938A | United States of America | A | |
| US4690939A | United States of America | A | |
| US4690940A | United States of America | A | |
| US4692437A | United States of America | A | |
| US4692459A | United States of America | A | |
| US4695577A | United States of America | A | |
| US4695582A | United States of America | A | |
| US4698355A | United States of America | A | |
| US4698356A | United States of America | A | |
| NO156695C | Norway | C | |
| US4707490A | United States of America | A | |
| AT385038B | Austria | B | |
| US4745124A | United States of America | A | |
| IT1193214B | Italy | B | |
| FI76558B | Finland | B | |
| FI76558C | Finland | C | |
| JPH01246257A | Japan | A | |
| JPH01250344A | Japan | A | |
| JPH0146507B2 | Japan | B2 | |
| ATA205181A | Austria | A | |
| ATA596279A | Austria | A | |
| HU199786B | Hungary | B |
Numbers
- Publication, DOCDB
- 73585
- Publication, EPODOC
- GR73585
- Application
- 59962
- Application, DOCDB
- 790159962
- Application, EPODOC
- GR19790159962
Classification
- CPC, 6
- C07K5/06173
- A61K38/00
- C07D207/16
- C07D207/22
- C07D207/50
- C07K5/06086
- IPC, 10
- A61K31 145
- A61K31 395
- A61K31 40
- A61K31 415
- A61K38 00
- C07D207 16
- C07D207 22
- C07D207 50
- C07K5 068
- C07K5 078
